J&J undercuts Celgene’s Pomalyst with $135K-per-year Darzalex price

Posted: November 17th, 2015  |  Company/topic: Celgene
Johnson & Johnson's new multiple myeloma treatment Darzalex (daratumumab) scored a speedy FDA approval, entering a market that's already crowded with last-ditch treatments. But the company is hopi…

Agios slips on mixed solid tumor data for its Celgene-partnered cancer drug

Posted: November 9th, 2015  |  Company/topic: Celgene
One of Agios Pharmaceuticals' blood cancer treatments demonstrated promise in a Phase I study against solid tumors, but the results fell short of some investors' expectations, sending the company's sh…

UPDATE 2-Drugmaker Celgene’s revenue misses as Revlimid sales slow

Posted: November 5th, 2015  |  Company/topic: Celgene
Nov 5 (Reuters) - Celgene Corp posted its smallest revenue growth in five quarters as sales of its blockbuster cancer treatment Revlimid slowed.

Celgene revenue rises on demand for cancer, psoriasis drugs

Posted: November 5th, 2015  |  Company/topic: Celgene
Nov 5 (Reuters) - Drugmaker Celgene Corp posted an 18 percent jump in quarterly revenue as demand for its cancer and psoriasis drugs increased.